Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Gaithersburg, MD, United States. The current CEO is Christopher Robert Cooper.
SHPH has IPO date of 2022-08-31, 9 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $990.36K.
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
